What is it? Why is it important?

“Lessons Learned” are insights, new knowledge and experience acquired during study planning, set-up, conduct, and completion

 

It requires that:

  • Study staff members are aware of the critical importance of capturing, and applying, newly acquired experience and knowledge throughout the study lifecycle
  • The SP-INV or Site-INV ensure that any new insights are appropriately documented (e.g. in the study`s Risk-Assessment-Form (RAF) established during study planning and updated during study conduct until completion)
  • The SP-INV implements an overall assessment of collected “Lessons Learned”, and establishes a process that ensures experiences are reviewed and:

 

Experiences can both be positive and negative. Either way, both types of experiences can be translated into a “Lesson Learned”.

What do I need to do?

As a SP-INV or Site-INV, upon study conclusion:

  • Ask yourself, which “Lessons Learned” turned out to be especially valuable in supporting the quality of the study?
  • Ask yourself, which “Lessons Learned” turned out to be especially valuable in protecting the integrity of the studies “Critical to Quality” (CtoQ) factors?
  • Provide a summary of valuable “Lessons Learned” with the aim to support a QbyD approach in future studies. Ensure a process is in place to ensure “Lessons Learned” are incorporated during the planning process.
  • Based on “Lessons Learned” establish quality processes (e.g. SOPs, Wis) that avoid the re-occurrence of previously unwanted effects or consequences during study conduct (e.g. risks to participant right and safety and/or data quality)

 

The study`s RAF is an excellent source used to review, document, and establish quality processes based on “Lessons Learned”. This is only possible if “Lessons Learned” were diligently documented during previous studies.

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular guideline

  • 3.10 Quality management

ICH E8(R1) – see in particular

  • 3.1 Quality by Design of clinical studies
  • 3.2 Critical to Quality Factors

ISO 9001 (access liable to costs) – see in particular section

  • QMS Requirements

Documents

Abbreviations
  • CtoQ – Critical to Quality
  • CTU – Clinical Trials Unit
  • ICH – International Council for Harmonisation
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • ISO – International Organization for Standardization
  • QbyD – Quality by Design
  • QMS – Quality Management System
  • Site-INV – Site Investigator
  • SOP – Standard Operating Procedures
  • SP-INV – Sponsor Investigator
  • RAF - Risk Assessment Form
  • WI – Working Instructions
Completion ↦ Quality and Risk ↦ Clinical Study Report ↦ Lessons Learned
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Completion ↦ Quality and Risk ↦ Clinical Study Report ↦ Lessons Learned